Home > Treatment Options > Tumor Suppressors > Clinical Trials >


Last Updated: 03/28/17

Status: Determined Ineffective for NF2


  • Trials
  • Other Uses

Hydroxycarbamide, is no longer used or recommended for the treatment of NF2.

Other Names Hydroxyurea, Hydroxycarbamide, Hydrea, N-Hydroxyurea, Litalir, Oxyurea, Onco-carbide, Biosupressin, Droxia, Hidrix
Trade Name Hydrea™ Droxia™, Apo-Hydroxyurea™ and Gen-Hydroxyurea™,
Treatment By Pill - Oral
Inhibitor An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Molecular Formula CH4N2O2
IUPAC hydroxyurea
ChemSpider 3530
PubChem CID 3657


  • Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG - www.ClinicalTrials.gov
  • Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV) - www.ClinicalTrials.gov
  • Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG - www.ClinicalTrials.gov
  • Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma - www.ClinicalTrials.gov

Other Uses

  • Myeloproliferative disease
  • Sickle-cell disease
  • AIDS
  • Second line treatment for psoriasis
  • Systemic mastocytosis
  • Chronic myelogenous leukemia (replaced by imatinib
  • Biochemical research as a DNA replication inhibitor
What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021